News and reporting on prostate cancer.
Informaticians at Spain's National Cancer Research Centre develop a methodology for evaluating likely drug efficacy based on specific patient genotypes.
A University of Michigan-led team found that the lncRNA ARLNC1 forms a feedback loop with the androgen receptor to promote progression in prostate cancer.
A small study finds differences between three genomic prostate cancer tests, Medscape reports.
The method uses hydrogel encapsulation, which mimics a tissue sample, in order to allow circulating tumor cell isolation and extraction through laser dissection.
At least half a dozen cancer phenotypes showed significant associations with GWAS variant-based polygenic risk scores in a new phenome-wide association study.
GenomeDx will test its Decipher GRID database of cancer genomic profiles with samples from Janssen-run prostate cancer clinical trials.
The company had total revenues of $193.5 million during the quarter, driven by continued increases in revenue and test volume for its more recently launched and acquired tests.
Test volume and revenues increased in the US, especially in prostate cancer. Meanwhile, international test volume was down but corresponding revenue increased.
In Cell this week: genome sequencing analysis of Egyptian bat, "chemistry-first" approach to find personalized lung cancer treatment targets, and more.
In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.
As the Canadian election season heats up, neither major party has really paid much attention to science, according to Nature News.
BBC News says the uncertainty over Brexit is affecting science funding in the UK.
A new app purports to tell users "how gay" they are by looking at their DNA, but experts tell Futurism that the app is bunk.
In Nature this week: human and great ape cerebral organoids reveal aspects of brain development unique to humans, and more.